Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib

Abstract Chronic myelogenous leukemia (CML) is a clonal hematologic malignancy of the myeloid lineage caused by the oncogenic BCR/ABL fusion protein that promotes CML cell proliferation and protects them against drug-induced apoptosis. In this study, we determine LATS1 and LATS2 expression in CML ce...

Full description

Bibliographic Details
Main Authors: Phatchanat Klaihmon, Chanchao Lorthongpanich, Pakpoom Kheolamai, Wannachai Saisaard, Surapol Issaragrisil
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Subjects:
Chronic myelogenous leukemia
Hippo pathway
LATS kinase
Apoptosis
Imatinib
Online Access:https://doi.org/10.1038/s41598-024-54728-z

Internet

https://doi.org/10.1038/s41598-024-54728-z

Similar Items